Affimed, Artiva to Advance Combo of Innate Cell Engager, Off-the-Shelf Allogeneic NK Cell Therapy

 

• Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients
  

• Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patients

• AB-101 is a clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived NK cell manufactured at large scale via Artiva’s AlloNKTM platform as a universal ADCC-enhancing cell therapy

• In preclinical studies, the combination of AFM13 and AB-101 demonstrated potent anti-tumor activity

• An investigational new drug (IND) submission to the U.S. Food and Drug Administration (FDA) is planned for the first half of 2023

• Affimed to receive 67% of the combination therapy revenues, and Artiva to receive 33%

• Conference call and webcast scheduled for November 3, 2022 at 10:30 a.m. EDT/15:30 CET

Affimed and Artiva will host a conference call and webcast on November 3, 2022, at 10:30 a.m. EDT / 15:30 CET to discuss this partnership and next steps in the development of AFM13 in combination with AB-101. The conference call will be available via phone and webcast. A live audio webcast of the conference call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/.

To access the call by phone, please use link https://register.vevent.com/register/BIca92c598dd7a41319b8a09f5f7ce08bf, and you will be provided with dial in details and a pin number.

Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.

A replay of the webcast will be accessible at the same link for 30 days following the call.

https://finance.yahoo.com/news/affimed-artiva-biotherapeutics-announce-partnership-131500531.html